Antifungal therapy in European hospitals: data from the ESAC point-prevalence surveys 2008 and 2009

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11160%2F12%3A10124512" target="_blank" >RIV/00216208:11160/12:10124512 - isvavai.cz</a>

Výsledek na webu

<a href="http://onlinelibrary.wiley.com/doi/10.1111/j.1469-0691.2012.03973.x/full" target="_blank" >http://onlinelibrary.wiley.com/doi/10.1111/j.1469-0691.2012.03973.x/full</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/j.1469-0691.2012.03973.x" target="_blank" >10.1111/j.1469-0691.2012.03973.x</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Antifungal therapy in European hospitals: data from the ESAC point-prevalence surveys 2008 and 2009

Popis výsledku v původním jazyce

The study aimed to identify targets for quality improvement in antifungal use in European hospitals and determine the variability of such prescribing. Hospitals that participated in the European Surveillance of Antimicrobial Consumption Point PrevalenceSurveys (ESAC-PPS) were included. The WHO Anatomical Therapeutic Chemical (ATC) classification for antimycotics for systemic use (J02) 2009 version was used. Demographic data and information about indications and diagnoses were collected in 2008 and 2009. From 99 053 patients, 29 324 (29.6%) received antimicrobials. Antifungals represented 1529 of 40 878 (3.7%) antimicrobials. Antifungals were mainly (54.2%) administered orally. Hospital-acquired infections represented 44.5% of indications for antifungals followed by medical prophylaxis at 31.2%. The site of infection was not defined in 36.0% of cases but the most commonly targeted sites were respiratory (19.2%) and gastrointestinal (18.8%). The most used antifungal was fluconazole (60.

Název v anglickém jazyce

Antifungal therapy in European hospitals: data from the ESAC point-prevalence surveys 2008 and 2009

Popis výsledku anglicky

The study aimed to identify targets for quality improvement in antifungal use in European hospitals and determine the variability of such prescribing. Hospitals that participated in the European Surveillance of Antimicrobial Consumption Point PrevalenceSurveys (ESAC-PPS) were included. The WHO Anatomical Therapeutic Chemical (ATC) classification for antimycotics for systemic use (J02) 2009 version was used. Demographic data and information about indications and diagnoses were collected in 2008 and 2009. From 99 053 patients, 29 324 (29.6%) received antimicrobials. Antifungals represented 1529 of 40 878 (3.7%) antimicrobials. Antifungals were mainly (54.2%) administered orally. Hospital-acquired infections represented 44.5% of indications for antifungals followed by medical prophylaxis at 31.2%. The site of infection was not defined in 36.0% of cases but the most commonly targeted sites were respiratory (19.2%) and gastrointestinal (18.8%). The most used antifungal was fluconazole (60.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FR - Farmakologie a lékárnická chemie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2012

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Clinical Microbiology and Infection

ISSN

1198-743X

e-ISSN

—

Svazek periodika

18

Číslo periodika v rámci svazku

10

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

7

Strana od-do

"E389"-"E395"

Kód UT WoS článku

000308579400003

EID výsledku v databázi Scopus

—